Stereotactic ablative radiation therapy for subcentimeter lung tumors: clinical, dosimetric, and image guidance considerations.

Purpose: Use of stereotactic ablative radiation therapy (SABR) for subcentimeter lung tumors is controversial. We report our outcomes for tumors with diameter ≤1 cm and their visibility on cone beam computed tomography (CBCT) scans and retrospectively evaluate the planned dose using a deterministic...

Descripción completa

Detalles Bibliográficos
Publicado en:International Journal of Radiation Oncology, Biology, Physics Vol. 90; no. 4; pp. 843 - 850
Autores principales: Louie, Alexander V, Senan, Suresh, Dahele, Max, Slotman, Ben J, Verbakel, Wilko F A R
Formato: research Journal Article
Publicado: Pergamon Press - An Imprint of Elsevier Science Nov2014
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103873896&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 103873896
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        03603016
        1ZQ
      jtl: International Journal of Radiation Oncology, Biology, Physics
      issn: 03603016
      maglogo: N
    pubinfo:
      dt: Nov2014
      vid: 90
      iid: 4
      pid: 2410
      pub: Pergamon Press - An Imprint of Elsevier Science
    artinfo:
      ui:
        103873896
        NLM25585783
        2012868590
        10.1016/j.ijrobp.2014.06.064
        NLM25585783
        103873896
      ppf: 843
      ppct: 7
      formats:
      tig:
        atl: Stereotactic ablative radiation therapy for subcentimeter lung tumors: clinical, dosimetric, and image guidance considerations.
      aug:
        au:
          Louie, Alexander V
          Senan, Suresh
          Dahele, Max
          Slotman, Ben J
          Verbakel, Wilko F A R
        affil: Department of Radiation Oncology, VU University Medical Center, Amsterdam, the Netherlands; Department of Radiation Oncology, London Regional Cancer Program, University of Western Ontario, London, Canada; Department of Epidemiology, Harvard School of Public Health, Harvard University, Boston, Massachusetts. Electronic address: Dr.alexlouie@gmail.com.
      sug:
        subj:
          Algorithms
          Lung Neoplasms Radiography
          Lung Neoplasms Surgery
          Radiosurgery Methods
          Radiation Dosage
          Body Weights and Measures
          Tomography, X-Ray Computed
          Female
          Human
          Lung Neoplasms Pathology
          Male
          Radiotherapy, Computer-Assisted Methods
          Radiotherapy
          Respiration
          Retrospective Design
          Female
          Male
      ab: Purpose: Use of stereotactic ablative radiation therapy (SABR) for subcentimeter lung tumors is controversial. We report our outcomes for tumors with diameter ≤1 cm and their visibility on cone beam computed tomography (CBCT) scans and retrospectively evaluate the planned dose using a deterministic dose calculation algorithm (Acuros XB [AXB]). Methods and Materials: We identified subcentimeter tumors from our institutional SABR database. Tumor size was remeasured on an artifact-free phase of the planning 4-dimensional (4D)-CT. Clinical plan doses were generated using either a pencil beam convolution or an anisotropic analytic algorithm (AAA). All AAA plans were recalculated using AXB, and differences among D95 and mean dose for internal target volume (ITV) and planning target volume (PTV) on the average intensity CT dataset, as well as for gross tumor volume (GTV) on the end respiratory phases were reported. For all AAA patients, CBCT scans acquired during each treatment fraction were evaluated for target visibility. Progression-free and overall survival rates were calculated using the Kaplan-Meier method. Results: Thirty-five patients with 37 subcentimeter tumors were eligible for analysis. For the 22 AAA plans recalculated using AXB, Mean D95 ± SD values were 2.2 ± 4.4% (ITV) and 2.5 ± 4.8% (PTV) lower using AXB; whereas mean doses were 2.9 ± 4.9% (ITV) and 3.7 ± 5.1% (PTV) lower. Calculated AXB doses were significantly lower in one patient (difference in mean ITV and PTV doses, as well as in mean ITV and PTV D95 ranged from 22%-24%). However, the end respiratory phase GTV received at least 95% of the prescription dose. Review of 92 CBCT scans from all AAA patients revealed that the tumor was visualized in 82 images, and its position could be inferred in other images. The 2-year local progression-free survival was 100%. Conclusions: Patients with subcentimeter lung tumors are good candidates for SABR, given the dosimetry, ability to localize tumors with image guidance, and excellent local control.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N